Minimizing hypoglycemia in diabetes

No Thumbnail Available
Issue Date
Embargo End Date
Amiel, Stephanie A.
Aschner, Pablo
Childs, Belinda P.
Cryer, Philip E.
de Galan, Bastiaan
Heller, Simon R.
Frier, Brian M.
Gonder-Frederick, Linda
Jones, Timothy
Khunti, Kamlesh

Amiel, Stephanie A.; Aschner, Pablo; Childs, Belinda P.; Cryer, Philip E.; de Galan, Bastiaan; Heller, Simon R.; Frier, Brian M.; Gonder-Frederick, Linda; Jones, Timothy; Khunti, Kamlesh; Leiter, Lawrence A.; Luo, Yingying; Vigersky, Robert; Zoungas, Sophia. 2015. Minimizing hypoglycemia in diabetes. Diabetes Care, August 2015:vol. 38:no. 8:pp 1583-1591


Hypoglycemia caused by treatment with a sulfonylurea, a glinide, or insulin coupled with compromised defenses against the resulting falling plasma glucose concentrations is a problem for many people with diabetes. It is often recurrent, causes significant morbidity and occasional mortality, limits maintenance of euglycemia, and impairs physiological and behavioral defenses against subsequent hypoglycemia. Minimizing hypoglycemia includes acknowledging the problem; considering each risk factor; and applying the principles of intensive glycemic therapy, including drug selection and selective application of diabetes treatment technologies. For diabetes health-care providers treating most people with diabetes who are at risk for or are suffering from iatrogenic hypoglycemia, these principles include selecting appropriate individualized glycemic goals and providing structured patient education to reduce the incidence of hypoglycemia. This is typically combined with short-term scrupulous avoidance of hypoglycemia, which often will reverse impaired awareness of hypoglycemia. Clearly, the risk of hypoglycemia is modifiable.

Table of Content
Click on the DOI link to access the article (may not be free).